Company intelligence / Profile preview
Seekyo Therapeutics
- Ownership
- Private
- Employees
- ~7
- Development stage
- Preclinical
Overview
Seekyo Therapeutics has developed a proprietary platform called SKY™, enabling the design of "Tumor Activated Therapy™" that targets functional proteins in the tumor microenvironment. Their lead compound SKY01 has demonstrated efficacy and safety in both small and large animal models across several solid tumor types. The company remains pre-clinical with no human data yet reported but claims unprecedented antitumor efficacy versus standards of care in preclinical studies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (cytotoxic drugs)Immuno-stimulants (immunotherapy agents)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Seekyo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seekyo Therapeutics.